GBG Research at ESMO Virtual Meeting 2020

ePoster #248TiP Date: 17.09.2020
Speaker: Sibylle Loibl (Neu-Isenburg, Germany)
GeparDouze study (GBG 96): A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Loibl S, Rastogi P, Seiler S, et al.

ePoster #176P Date: 17.09.2020
Speaker: Jan Hauke (Köln, Germany)
GeparOLA study (GBG 90): Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Hauke J, Ernst C, Fasching PA, et al.

Mini oral presentation #168MO Date: 18.09.2020 Session: Mini Oral - Breast cancer, early stage
Chairs: Hope S. Rugo (San Francisco, CA, United States of America), Prudence Francis (Melbourne, VIC, Australia), Shaheenah Dawood (Dubai, United Arab Emirates)
Speaker: Theresa Link (Dresden, Germany)
GeparX study (GBG 88): Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
Link T, Blohmer J-U, Just M, et al.

Oral presentation #160O Date: 20.09.2020 Time: 12:54 - 13:06 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Andreas Schneeweiss (Heidelberg, Germany)
GeparOcto study (GBG 84): Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Schneeweiss A, Möbus V, Tesch H, et al.

External Presentation #LBA12 Date: 20.09.2020 Time: 13:26 - 13:38 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Erica L. Mayer (Boston, United States of America)
PALLAS study (GBG 87): A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

• See the full  ESMO-Programme online